LXEO

Lexeo Therapeutics, Inc.

LXEO · CIK 0001907108 · Annual (10-K) · Last 2 years

Financial Trends

Revenue
20232024
Net Income−$98M
20232024
Operating CF−$81M
20232024
Free Cash Flow−$82M
20232024

Income Statement

MetricFY 2024FY 2023
Revenue$0.0B
Cost of Revenue
Gross Profit
R&D Expense$0.1B$0.1B
SG&A Expense
Operating Income$-0.1B$-0.1B
Net Income$-0.1B$-0.1B
EPS (Basic)$-3.09$-12.40
EPS (Diluted)$-3.09$-12.40

Balance Sheet

MetricFY 2024FY 2023
Total Assets$0.1B$0.1B
Current Assets$0.1B$0.1B
Cash & Equivalents$0.0B$0.1B
Total Liabilities$0.0B$0.0B
Current Liabilities$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B

Cash Flow Statement

MetricFY 2024FY 2023
Operating Cash Flow$-0.1B$-0.1B
Investing Cash Flow$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B
Financing Cash Flow$0.1B$0.1B